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IN THE TREATMENT OF MYASTHENIA GRAVIS
Petar Kes1 and Vanja Ba¹iÊ-Kes2
1Department of Nephrology and Dialysis, and 2Department of Neurology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY · Myasthenia gravis is an antibody-mediated autoimmune disease in which circulating
acetylcholine receptor (AChR) antibodies have been identified that bind to the receptor sites in vol-
untary muscles, thereby damaging and blocking the receptors. Selective removal of the blocking
antibody by plasmapheresis or specific immunoadsorption provides important methods in the treat-
ment of patients with myasthenia gravis. Novel immunoadsorbent columns have been developed
especially for the treatment of patients with myasthenia gravis, using a specific affinity ligand (Tor-
pedo  183-200, a synthetic peptide) to remove the blocking antibody. This immunoadsorbent pro-
duced specific removal of the blocking antibody without reducing other plasma proteins. Clinical
improvement was observed in 78% of myasthenia gravis patients. There were no adverse effects.
Key words: Myasthenia gravis, therapy; Plasmapheresis
Introduction
In the past 30 years, several studies have documented
the effect of plasmapheresis and immunoadsorption in
eliminating pathogenic autoantibodies (ABs) and im-
mune complexes (ICs) from circulation. In almost any
immune disease, extracorporeal therapy is tried in criti-
cal situations, but only in thrombotic-thrombocytopenic
purpura, cryoglobulinemia, Goodpasture’s syndrome,
Guillain-Barre syndrome, and crisis in myasthenia gravis
plasmapheresis is standard therapy1-3.
Myasthenia gravis is a chronic disease which most
commonly occurs in young adults, and progresses with re-
misssions and exacerbations. It is characterized by the
activity-induced abnormal muscle fatigability with typi-
cal drooping of eyelids and jaw, nasal voice, slurred speech,
and weakness of proximal extremities. It involves progres-
sive failure of impulse conduction at the neuromuscular
junction. Myasthenia gravis is an autoimmune disorder in
which neuromuscular transmission is impaired by anti-
acetylcholine receptor (AChR) antibodies. The anti-
AChR antibodies involved in the pathogenesis of myas-
thenia gravis are classified into two subclasses: one is the
blocking antibody, and the other is the binding antibody.
The blocking antibody is known to directly block the ace-
tylcholine (ACh) binding site of AChR, and this is one
of the cases of myasthenia gravis. From this point of view,
removal of the blocking antibody is an important method
in the treatment of myasthenia gravis.
Plasmapheresis
Plasmapheresis is a method of treatment aimed at re-
moving AChR antibodies from the plasma to decrease the
autoimmune activity. Several uncontrolled trials and nu-
merous anecdotal reports describe dramatic post-plasma-
phereis treatment results2,4. There has been no controlled
trial with plasmapheresis in myasthenia gravis patients,
nevertheless, the 1985 NIH Consensus Conference con-
cluded that plasmapheresis might be useful in increasing
muscle strength during the pre- and post-thymectomy
period, and in decreasing symptoms during the initiation
Correspondence to: Prof. Petar Kes, M.D., Ph.D., Department of Neph-
rology and Dialysis, Sestre milosrdnice University Hospital,
Vinogradska c. 29, HR-10000 Zagreb, Croatia
Receved January 4, 2000, accepted May 22, 2000
P. Kes and V. Ba¹iÊ-Kes Plasmapheresis in myasthenia gravis
40 Acta clin Croat, Vol. 40, No. 1, 2001
of immunosuppressive therapy as well as in acute crisis1.
Plasmapheresis was also found beneficial in four of eight
patients with seronegative myasthenia gravis5. The pos-
sible explanation is inability of the assay to detect AChR
antibody or existence of antibodies that may be directed
against a different antigenic determinant of the neuro-
muscular junction3.
The recommended plasmapheresis prescription is 5
treatments over a one-week period. Each treatment
should equal 1.5 plasma volume (PV), which can be re-
placed with 5% albumin. If the patient is in the immedi-
ate prethymectomy period, partial replacement of approxi-
mately one liter of fresh frozen plasma (FFP) given to-
ward the end of the last treatment should help reverse the
expected depletion coagulopathy. Although the levels of
AChR antibodies are unlikely to be observed, the expected
declines in AChR antibodies reveal an excellent correc-
tion with the calculated total IgG removal kinetics6.
Specific Immunoadsorption
Takamori et al.7 report that the  183-200 segment of
the Torpedo Californica AChR binding site recognized by
the blocking antibody, and this Torpedo peptide showed a
much more potent binding ability than the human pep-
tide. Based on these studies, Miyahara et al.8 have de-
signed a new immunoadsorbent especially for the trea-
ment of myasthenia gravis, using Torpedo  183-200, a syn-
thetic peptide, as a specific affinity ligand to remove the
blocking antibody. The immunoadsorbent column (Me-
disorba MG column) is packed with 50 ml of porous cel-
lulose beads covalently immobilized with the synthetic
peptide and sterilized by autoclaving. The safety of the
immunoadsorbent has been confirmed by various toxic-
ity tests. The release of the peptide from the adsorbent was
minimal. The adsorption performance of Medisorba MG
column was firstly evaluated in vitro using the plasma
from myasthenia gravis patients. The immunoadsorbent
produced specific and significant removal of the blocking
antibody without reducing IgG and albumin concentra-
tions in an in vitro study. In clinical evaluation, Ide et al.9
carried out 77 treatments of plasma perfusion in 19 my-
asthenia gravis patients. The removal rate of anti-AChR
blocking antibody and anti-AChR binding antibody was
approximately 40.2% and 12.4%, respectively. The block-
ing antibody was specifically removed in these immuno-
adsorption treatments, without any significant reduction
of the plasma protein level. Clinical improvement was
observed in 78% of patients with myasthenia gravis, and
no adverse effects were recorded9. The Medisorba MG
column has been confirmed as a useful tool in therapy for
myasthenia gravis.
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Saæetak
LIJE»ENJE MIASTENIJE GRAVIS POMOÆU PLAZMAFEREZE I SPECIFI»NE IMUNOADSORPCIJE
P. Kes i V. Ba¹iÊ-Kes
Miastenija gravis je autoimuna bolest kod koje se cirkulirajuÊa protutijela protiv receptora za acetilkolin veæu za receptorska
mjesta na popreËnoprugastim mi¹iÊima i dovode do blokiranja i o¹teÊenja receptora. BlokirajuÊa protutijela mogu se specifiËno
odstraniti iz plazme bolesnika s miastenijom gravis pomoÊu plazmafereze ili specifiËne imunoadsorpcije. Nove kolone za
imunoadsorpciju u kojima se kao specifiËni vezaË za blokirajuÊe protutijelo acetilkolinskih receptora rabi sintetiËki peptid
Torpedo  183-200 pokazale su visoku specifiËnost u odstranjivanju blokirajuÊih protutijela, a da pritom nisu utjecale na
koncentraciju drugih bjelanËevina u plazmi. Do kliniËkog pobolj¹anja do¹lo je u 78% bolesnika s miastenijom gravis, a da nije
zabiljeæena niti jedna nuspojava.
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